Sol-Gel Technologies (SLGL) Total Debt (2016 - 2025)
Sol-Gel Technologies (SLGL) posted quarterly Total Debt of $1.4 million for Q2 2025, down 97.93% quarter-over-quarter from $65.3 million in Q4 2017.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Total Debt (2016 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Total Debt for 3 consecutive years, with $1.4 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Total Debt changed N/A year-over-year to $1.4 million; the TTM figure through Jun 2025 stood at $1.4 million (changed N/A YoY), while the FY2017 annual figure was $65.3 million, up 74.99% from the prior year.
- Total Debt eased to $1.4 million in Q2 2025 per SLGL's latest filing, from $65.3 million in the prior quarter.
- Across five years, Total Debt topped out at $1.4 million in Q2 2025 and bottomed at $1.4 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.07 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.34 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 1.36 Mn |
| Dec 31, 2018 | 65.34 Mn |
| Jun 30, 2018 | 65.34 Mn |
| Dec 31, 2017 | 65.34 Mn |
| Dec 31, 2016 | 37.34 Mn |